论文部分内容阅读
美国国立心、肺、血液研究所(National Heart,Lung and Blood Institute——NHLBI)对Ⅱ型高血脂症患者进行了研究;观察消胆胺和饮食控制对冠状动脉硬化进展和血脂的影响。143例冠状动脉疾病(CAD)患者(有心肌梗塞病史,心绞痛,运动试验阳性,或胸透示冠状动脉钙化),经过低胆固醇、低脂饮食后,其血浆低密度脂蛋白-胆固醇(LDL-C)仍高者,被列为观察对象。凡左下降支主干狭窄75%以上,或冠状动脉管腔狭窄不到20%者均被剔除。消胆胺的剂量为每天24克。试验采用药物和安慰剂
The National Center for Heart, Lung and Blood Institute (NHLBI) studied patients with type II hyperlipidemia and observed the effect of cholestyramine and dietary control on progression of coronary atherosclerosis and blood lipids. 143 patients with coronary artery disease (CAD) had a history of myocardial infarction, angina pectoris, exercise test positive or thoracoscopic coronary artery calcification. After low-cholesterol and low-fat diet, their plasma LDL- C) is still high, was classified as the object of observation. Where the left descending branch of more than 75% of the stenosis, or coronary stenosis less than 20% were removed. Cholestyramine dose of 24 grams per day. The trial used medications and placebo